Skip to content
ClinCalc Pro
Menu
Analgesic Pregnancy: SPC §4.6, verbatim: 'Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. There are no adequate data from the use of fentanyl in pregnant women. Fentanyl can cross the placenta in early pregnancy. Studies in animals have shown some reproductive toxicity. The potential risk for humans is unknown. Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.' BREASTFEEDING: 'Administration to nursing women is not recommended as fentanyl may be secreted in breast milk and may cause respiratory depression in the infant. Therefore breast-feeding or use of expressed breast milk is not recommended within 24 hours of treatment.' FERTILITY: no clinical data; reduced female fertility in rats at maternally toxic doses.

Fentanyl

Brand names: Sublimaze, Actiq, Duragesic

Fentanyl is a potent synthetic opioid analgesic used in emergency and critical care for severe acute pain and to facilitate procedures and rapid-sequence induction.

Adult dose

Dose: Injection only — with spontaneous respiration: initial 50–200 micrograms IV, supplemental 50 micrograms. SPC qualifier, verbatim: 'Doses in excess of 200 micrograms are for use in anaesthesia only.' (With assisted ventilation the SPC gives initial 300–3500 micrograms and supplemental 100–200 micrograms — see notes.)
Route: Intravenous, as a bolus or by infusion; intramuscular is also licensed. Verbatim: 'Fentanyl should be given only in an environment where the airway can be controlled and by personnel who can control the airway.' 'To avoid bradycardia, it is recommended to administer a small intravenous dose of an anti-cholinergic just before anaesthetic induction.' The intranasal and buccal routes shown on this page are NOT covered by this injection SPC.
Frequency: Initial dose then supplemental doses titrated to response (50 micrograms with spontaneous respiration; 100–200 micrograms with assisted ventilation). May alternatively be given by infusion — see notes.
SPC §4.2 verbatim adult table — 'Spontaneous Respiration: Initial 50-200 micrograms, Supplemental 50 micrograms. Assisted Ventilation: Initial 300-3500 micrograms, Supplemental 100-200 micrograms. Doses in excess of 200 micrograms are for use in anaesthesia only.' 'The dose of fentanyl should be individualised according to age, body weight, physical status, underlying pathological condition, use of other drugs and type of surgery and anaesthesia.' PREMEDICATION: 'As a premedicant, 1-2 ml fentanyl may be given intramuscularly 45 minutes before induction of anaesthesia' — at the fetched product strength of 50 micrograms/ml that is 50–100 micrograms (arithmetic, from the product name; the SPC states the volume). DURATION: '2 ml fentanyl may be expected to provide sufficient analgesia for 10-20 minutes in surgical procedures involving low pain intensity' (= 100 micrograms); '10 ml fentanyl injected as a bolus gives analgesia lasting about one hour' (= 500 micrograms); 'Giving a dose of 50 micrograms/kg fentanyl will provide intense analgesia for some four to six hours, for intensely stimulating surgery.' INFUSION: 'In ventilated patients, a loading dose of fentanyl may be given as a fast infusion of approximately 1 microgram/kg/min for the first 10 minutes followed by an infusion of approximately 0.1 micrograms/kg/min... Unless it is planned to ventilate post-operatively, the infusion should be terminated at about 40 minutes before the end of surgery. Lower infusion rates, e.g. 0.05-0.08 micrograms/kg/minute are necessary if spontaneous ventilation is to be maintained. Higher infusion rates (up to 3 micrograms/kg/minute) have been used in cardiac surgery.' ELDERLY/DEBILITATED: 'the initial dose should be reduced in the elderly (>65 years of age) and in debilitated patients.' OBESITY: 'In obese patients there is a risk of overdosing if the dose is calculated based on body weight. Obese patients should have dosage calculated according to their estimated lean body mass.' INCOMPATIBILITY: chemically incompatible with pentobarbital sodium, thiopentone and methohexitone. NO MAXIMUM DOSE is stated in either fetched label — the '200 micrograms' figure is a restriction on setting (anaesthesia only), not a stated ceiling, so no maxDose is published. US cross-check (§2.2): 'Initiate treatment in adults with 50 mcg to 100 mcg'; premedication 50–100 micrograms IM 30–60 minutes before surgery; adjunct to regional anaesthesia 50–100 micrograms IM or slowly IV over one to two minutes; postoperatively (recovery room) 50–100 micrograms IM, repeatable in one to two hours.

Paediatric dose

Dose: 1 micrograms/kg
Route: Intravenous — children aged 2 to 11 years (the SPC table gives the same figures for spontaneous respiration and for assisted ventilation)
Frequency: Initial dose, then supplemental doses of 1–1.25 micrograms/kg as required
Concentration: 50 micrograms/ml
The calculator uses the LOWER end of the SPC's initial range. SPC §4.2 paediatric table, verbatim — 'Children aged 2 to 11 years old: Spontaneous Respiration 2-11 yrs Initial 1-3 micrograms/kg, Supplemental 1-1.25 micrograms/kg; Assisted Ventilation 2-11 yrs Initial 1-3 micrograms/kg, Supplemental 1-1.25 micrograms/kg.' 'Children aged 12 to 17 years old: Follow adult dosage.' Verbatim safety statement: 'Techniques that involve analgesia in a spontaneous breathing child should only be used as part of an anaesthetic technique, or given as part of a sedation/analgesia technique with experienced personnel in an environment that can manage sudden chest wall rigidity requiring intubation, or apnoea requiring airway support.' No figure is given in this SPC for children under 2 years; the US label states 'The safety and efficacy of Fentanyl Citrate Injection in pediatric patients under two years of age has not been established.' The concentration used for the volume calculation is the fetched product strength — Fentanyl 50 microgram/ml Injection, i.e. 50 micrograms per mL. Intranasal dosing is NOT covered by this label. Verify all under-18 dosing against a children's formulary before administration.

Dose adjustments

Renal

SPC §4.2, verbatim: 'Renal Impairment: In patients with renal impairment reduced dosing of fentanyl should be considered and these patients should be observed carefully for signs of fentanyl toxicity.' US label §8.5 adds: 'Fentanyl is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function... care should be taken in dose selection, and it may be useful to monitor renal function.'

Hepatic

Not stated — no hepatic-impairment dosing statement appears in any fetched section of the UK SPC or the US label. The only mention is US §8.5, which notes elderly patients more often have 'decreased hepatic, renal, or cardiac function'. Verify before use in hepatic impairment.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Paediatric weight-based calculator

The calculator uses the LOWER end of the SPC's initial range. SPC §4.2 paediatric table, verbatim — 'Children aged 2 to 11 years old: Spontaneous Respiration 2-11 yrs Initial 1-3 micrograms/kg, Supplemental 1-1.25 micrograms/kg; Assisted Ventilation 2-11 yrs Initial 1-3 micrograms/kg, Supplemental 1-1.25 micrograms/kg.' 'Children aged 12 to 17 years old: Follow adult dosage.' Verbatim safety statement: 'Techniques that involve analgesia in a spontaneous breathing child should only be used as part of an anaesthetic technique, or given as part of a sedation/analgesia technique with experienced personnel in an environment that can manage sudden chest wall rigidity requiring intubation, or apnoea requiring airway support.' No figure is given in this SPC for children under 2 years; the US label states 'The safety and efficacy of Fentanyl Citrate Injection in pediatric patients under two years of age has not been established.' The concentration used for the volume calculation is the fetched product strength — Fentanyl 50 microgram/ml Injection, i.e. 50 micrograms per mL. Intranasal dosing is NOT covered by this label. Verify all under-18 dosing against a children's formulary before administration.

Verify in a children's formulary

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1, or to other opioids (SPC §4.3)
  • Respiratory depression, obstructive airways disease (SPC §4.3)
  • Concurrent administration with monoamine oxidase inhibitors, or within 2 weeks of their discontinuation (SPC §4.3)
  • US label §4 lists only 'Hypersensitivity to fentanyl (e.g., anaphylaxis)' — the UK SPC list above is the wider one and is the one applied here

Side effects

  • Very common (≥1/10), §4.8: muscle rigidity — 'which may also involve the thoracic muscles' (10.4% in pooled trial data); nausea (26.1%); vomiting (18.6%)
  • Common (≥1/100 to <1/10): hypotension (8.8%); hypertension (8.8%); bradycardia (6.1%); sedation (5.3%); tachycardia; arrhythmia; venous pain; dyskinesia; dizziness; agitation; laryngospasm; bronchospasm; apnoea; postoperative confusion; airway complication of anaesthesia
  • Uncommon (≥1/1,000 to <1/100): euphoric mood; headache; visual disturbance; phlebitis; blood pressure fluctuation; hyperventilation; hiccups; dysphagia; allergic dermatitis; chills; hypothermia; drug withdrawal syndrome
  • Not known: respiratory depression; cardiac arrest; convulsions; loss of consciousness; myoclonus; delirium; drug dependence; hypersensitivity including anaphylactic shock, anaphylactic reaction and urticaria; pruritus
  • With a concomitant neuroleptic: chills and/or shivering, restlessness, postoperative hallucinatory episodes and extrapyramidal symptoms
  • US label §6 (cross-check): 'the most common serious adverse reactions reported to occur with fentanyl are respiratory depression, apnea, rigidity and bradycardia; if these remain untreated, respiratory arrest, circulatory depression or cardiac arrest could occur'

Monitoring

  • Airway and ventilation — 'Fentanyl should be given only in an environment where the airway can be controlled and by personnel who can control the airway' (SPC §4.2/§4.4)
  • US §2.1, verbatim: 'Ensure that an opioid antagonist, resuscitative and intubation equipment, and oxygen are readily available.'
  • US §2.1, verbatim: 'Monitor vital signs routinely. As with other potent opioids, the respiratory depressant effect of fentanyl may persist longer than the measured analgesic effect. The total dose of all opioid agonists administered should be considered by the practitioner before ordering opioid analgesics during recovery from anesthesia.'
  • Blood pressure — 'Following intravenous administration of fentanyl, a transient fall in blood pressure may occur, especially in hypovolaemic patients. Appropriate measures to maintain a stable arterial pressure should be taken.' (SPC §4.4)
  • Muscle/chest wall rigidity — listed as a very common reaction 'which may also involve the thoracic muscles'; be prepared to manage rigidity requiring intubation
  • Renal impairment — 'observed carefully for signs of fentanyl toxicity' (SPC §4.2)
  • Signs of misuse, abuse, addiction or tolerance on repeated use, with regular review of the clinical need for analgesic treatment (SPC §4.4)

Clinical monograph

How it works

It is a strong agonist at mu-opioid receptors, producing rapid, short-lasting analgesia and sedation; its high lipophilicity gives fast onset and a short duration after a single dose.

Prescribing in practice

  • It is a high-potency opioid that can cause rapid respiratory depression and apnoea, so it must only be used where airway support, oxygen, monitoring and naloxone are immediately available.
  • Rapid intravenous administration of higher doses can precipitate chest-wall and glottic rigidity, impairing ventilation.
  • Effects are markedly potentiated by other CNS depressants and benzodiazepines, increasing the risk of profound sedation and respiratory compromise.

Monitoring

Monitor respiratory rate, oxygen saturation, sedation level and blood pressure continuously during and after administration.

Counselling the patient

  • This is a strong, fast-acting painkiller that can slow your breathing, so you will be closely watched.
  • Tell staff at once if you feel very drowsy or short of breath.
  • Avoid alcohol and other sedating medicines around the time it is given.

Evidence & guidelines

Fentanyl is an established opioid for acute severe pain and procedural use in emergency and anaesthetic practice.

Reference: NICE; RCEM Pain in Adults Clinical Standards 2022; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

📚 MRCEM Revision

Featured in these MRCEM clinical pathways

Fentanyl is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.

MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.